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Summary
Long-	term	functional	outcomes	of	sofosbuvir-	based	antiviral	treatment	were	evalu-
ated	in	a	cohort	study	involving	16	Italian	centres	within	the	international	compas-
sionate	 use	 programme	 for	 post-	transplant	 hepatitis	 C	 virus	 (HCV)	 recurrence.	
Seventy-	three	patients	with	cirrhosis	(n=52)	or	fibrosing	cholestatic	hepatitis	(FCH,	
n=21)	received	24-	week	sofosbuvir	with	ribavirin±pegylated	interferon	or	interferon-	
free	 sofosbuvir-	based	 regimen	 with	 daclatasvir/simeprevir+ribavirin.	 The	 patients	
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1  | INTRODUCTION
The	 recurrence	 of	 hepatitis	 C	 virus	 (HCV)	 infection	 is	 universal	 in	
HCV-	RNA	positive	liver	transplants	(LT).1-3	Patients	with	severe	HCV	
recurrence	progress	rapidly	to	end-	stage	illness	and,	if	re-	LT	cannot	be	
performed,	 to	 graft	 loss	 and/or	 death.4,5	Moreover,	 the	 progression	
of	 post-	LT	HCV	 recurrence	 can	 be	 particularly	 fast	 in	 patients	with	
features	of	fibrosing	cholestatic	hepatitis	(FCH).6-9	Successful	antiviral	
therapy	of	HCV	recurrence	has	been	shown	to	allow	longer	survival	
and better clinical outcome.10	 In	 recent	years,	 therapeutic	manage-
ment	of	HCV	recurrence	has	changed	11-13	with	excellent	virological	
results	 of	 direct	 acting	 antivirals	 (DAAs).14-22	 Nevertheless,	 data	 on	
their	long-	term	outcomes	are	lacking	in	the	actual	literature.
The	 aim	 of	 this	 study	was	 to	 evaluate	 the	 long-	term	 outcomes	
of	sofosbuvir	 (SOF)-	based	treatment	 in	patients	with	severe	post-	LT	
HCV	recurrence.
2  | METHODS
2.1 | Patients
From	 April	 2013	 to	 July	 2014,	 consecutive	 patients	 with	 post-	LT	
HCV	 recurrence	 were	 enrolled	 in	 16	 Italian	 hepatology	 centres	 to	
receive	antiviral	treatment	with	DAAs	upon	individual	authorizations	
for	compassionate	use	from	 local	Ethical	Committees.	The	 inclusion	
criteria	were	as	follows:	age	≥18	years,	severe	hepatitis	C	recurrence,	
no	access	 to	experimental	 treatment	 and	estimated	 life	 expectancy	
≤6	months.	The	exclusion	criteria	were	as	follows:	inability	or	refusal	
to	give	 informed	consent,	pregnancy	and	unstable	 immunosuppres-
sive	regimen.
Seventy-	three	 LT	 recipients	with	 advanced	 HCV	 recurrence	 (52	
with	cirrhosis	and	21	with	FCH)	were	treated	for	24	weeks	with	SOF	
(400	mg	daily)	 in	combination	with	 ribavirin	 (RBV)	 (n=54),	pegylated	
interferon	(PegIFN)+RBV	(n=14),	daclatasvir	(DCV)	(n=4)	or	simeprevir	
(SMV)+RBV	(n=1).
Sustained	 virological	 response	 (SVR12)	was	 defined	 as	 negative	
HCV-	RNA	according	to	lower	limit	of	detection	(<25	IU/mL)	12	weeks	
after	end	of	treatment	(EOT).	Laboratory	analyses	included	HCV-	RNA,	
blood	 count,	 alanine	 transaminases	 (ALT),	 aspartate	 transaminases	
(AST),	 alkaline	 phosphatase	 (ALP),	 γ-	glutamyl	 transferases	 (γGT),	 al-
bumin,	 total	bilirubin,	 serum	creatinine	and	 international	normalized	
ratio	(INR).	Child-	Turcotte-	Pugh	(CTP)	and	Model	for	End-	Stage	Liver	
Disease	(MELD)	scores	were	reported.	Each	centre	confirmed	the	di-
agnosis	of	FCH	according	 to	 the	 following	 criteria	 (8):	 (i)	 prominent	
ductular	reaction	in	the	portal	tracts,	(ii)	cholestasis	defined	as	cana-
licular	bile	plugs	and/or	 intracellular	bile	pigment,	 (iii)	prominent	he-
patocyte	ballooning	with	lobular	disarray,	(iv)	any	degree	of	periportal	
sinusoidal/pericellular	 fibrosis,	 (v)	 >1-	month	 after	 transplantation,	
(vi)	 total	bilirubin>2.0	mg/dL,	 (vii)	γGT>150	U/L.	 In	patients	showing	
these	histological	features,	surgical	biliary	obstruction	and	thrombosis	
of	hepatic	artery	were	excluded.	Finally,	high	serum	HCV-	RNA	levels	
were	confirmed	(Table	2).
were	observed	for	a	median	time	of	103	(82-	112)	weeks.	Twelve	of	73	(16.4%)	died	
(10	non-	FCH,	2	FCH)	and	two	underwent	re-	LT.	Sustained	virological	response	was	
achieved	in	46	of	66	(69.7%):	31	of	47	(66%)	non-	FCH	and	15	of	19	(79%)	FCH	pa-
tients.	All	relapsers	were	successfully	retreated.	Comparing	the	data	of	baseline	with	
last	 follow-	up,	MELD	 and	Child-	Turcotte-	Pugh	 scores	 improved	 both	 in	 non-	FCH	
(15.3±6.5	vs	10.5±3.8,	P<.0001	and	8.4±2.1	vs	5.7±1.3,	P<.0001,	respectively)	and	
FCH	 (17.3±5.9	 vs	 10.1±2.8,	 P=.001	 and	 8.2±1.6	 vs	 5.5±1,	 P=.001,	 respectively).	
Short-	treatment	mortality	 was	 higher	 in	 patients	with	 baseline	MELD≥25	 than	 in	
those	 with	 MELD<25	 (42.9%	 vs	 4.8%,	 P=.011).	 Long-	term	 mortality	 was	 53.3%	
among	 patients	 with	 baseline	 MELD≥20	 and	 7.5%	 among	 those	 with	 MELD<20	
(P<.0001).	Among	deceased	patients	75%	were	Child-	Turcotte-	Pugh	class	C	at	base-
line,	while	among	survivors	83.9%	were	class	A	or	B	(P<.0001).	Direct	acting	antivirals-	
based	 treatments	 for	 severe	 post-	transplant	 hepatitis	 C	 recurrence,	 comprising	
fibrosing	cholestatic	hepatitis,	significantly	improve	liver	function,	even	without	viral	
clearance	and	permit	an	excellent	long-	term	survival.	The	setting	of	severe	HCV	re-
currence	may	require	the	identification	of	“too-	sick-	to-	treat	patients”	to	avoid	futile	
treatments.
K E Y W O R D S
antiviral	therapy,	fibrosing	cholestatic	hepatitis,	liver	transplant,	long-term	outcome,	severe	
hepatitis	C	virus	recurrence
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2.2 | Statistical analysis
Categorical	variables	are	expressed	as	number	(%),	and	quantitative	
variables	are	shown	as	mean	±	standard	deviation	or	as	median	(in-
terquartile	 range,	 IQR).	Chi-	square	or	Fisher’s	 exact	 test	was	used	
to	 compare	 categorical	 variables,	 while	 for	 quantitative	 variables	
the t	 test	 or	Mann-	Whitney’s	 test	 (unpaired	 data)	 or	 the	 t	 test	 or	
Wilcoxon’s	 test	 (paired	 data)	 were	 used.	 Survival	 analyses	 were	
evaluated	by	the	Kaplan-	Meier	method.	Statistical	significance	was	
established	 at	 a	 two-	tailed	P	 level	 <.05.	Data	 handling	 and	 analy-
sis	were	performed	with	SPSS	21.0	statistical	package	 (®SPSS	Inc.,	
Chicago,	IL,	USA).
3  | RESULTS
3.1 | Study population
Demographic	and	clinical	characteristics	of	 the	73	enrolled	patients	
are	 provided	 in	 Table	1.	 Figure	1	 shows	 the	 disposition	 of	 patients	
throughout	 the	 study.	Starting	 from	 the	enrolment,	 the	median	 fol-
low-	up	was	 724	 (574-	788)	 days.	 Twelve	 patients	 died	 (four	 before	
EOT,	 two	during	 the	 first	12	weeks	of	 follow-	up	and	six	after),	 two	
underwent	re-	LT	(one	before	EOT	and	one	afterwards).	Finally,	two	
patients	were	lost	on	follow-	up.	Overall	SVR12	rate	was	63%	(46/73)	
according	to	intention-	to-	treat	and	69.7%	(46/66)	according	to	per-	
protocol	 analysis.	 SVR12	 patients	 differed	 from	 non-	SVR12	 ones	
in	 terms	 of	 treatment	 schedule	 and	 CTP	 class	 (Table	 S1).	 Among	
non-	SVR12	patients,	19	of	20	survived	and	all	19	were	successfully	
re-	treated.
3.2 | Clinical outcomes
All	 liver	 function	 tests	 improved	 significantly	 during	 and	 after	
therapy.	 The	 MELD	 score	 was	 improved	 from	 baseline	 to	 last	
follow-	up	 (15	 [11-	19]	 vs	10	 [7-	13],	P<.0001,	 Fig.	 S1A).	Also	 the	
CTP	 score	 improved	 from	baseline	 to	 last	 follow-	up	 (8	 [7-	10]	 vs	
5	[5,6]	P<.0001,	Fig.	S1B).	This	 improvement	was	confirmed	also	
after	 subdividing	 the	patients	 in	 those	who	obtained	SVR12	and	
those	who	did	not.
After	 the	 observation	 period,	 59	 of	 73	 (80.8%)	 subjects	were	
alive	 (Figure	1).	 Four	 patients	 (5.5%)	 died	 during	 treatment	 (two	
kidney	 failure,	 one	 sepsis	 and	 one	 respiratory	 failure),	 and	 eight	
during	 follow-	up	 (four	 liver	 failure,	 one	HCC,	 one	 graft	 rejection,	
one	sepsis	and	one	severe	biliary	complication).	Table	S2	shows	the	
comparison	of	the	patients	who	died	with	those	who	were	alive	at	
last	follow-	up.
Nine	of	59	(15.3%)	with	available	data	on	last	follow-	up	presented	
relevant	 hepatic	 complications:	 one	 ascites	 requiring	 transjugular	
TABLE  1 Baseline	characteristics	in	overall	population	and	according	to	treatment	regimen
Overall 
(n=73)
SOF+RBV 
(n=54)
SOF+PegIFN+RBV 
(n=14)
SOF+DCV/
SMV+RBV (n=5)
Male	gender 54	(74%) 41	(76%) 11	(79%) 1	(20%)
Age	(y) 53	(49-	62) 53	(49-	62) 52	(49-	56) 55	(40-	66)
Time	from	LT	(mo) 26	(12-	53) 26	(13-	55) 21	(9-	78) 27	(15-	41)
FCH 21	(28.8%) 16	(29.6%) 5	(35.7%) 0
Previous	antiviral	treatment 46	(63%) 32	(59%) 11	(79%) 3	(60%)
Starting	RBV	dose	(mg) 600	(400-	800) 600	(400-	800) 900	(600-	1000) 600	(600-	600)
Starting	RBV	dose	(mg/kg) 10.5	(6.9-	13) 9.5	(6.8-	12.5) 12.2	(9.9-	13.7) 9.2	(9.2-	9.2)
HCV	Genotype	1a/1b/2/3/4 20/37/1/6/9 15/27/1/6/5 3/7/0/0/4 2/3/0/0/0
HCV-	RNA	(Log10	IU/mL) 6	(5.2-	6.4) 6	(5.3-	6.5) 6	(4.9-	6.3) 6	(5-	6.2)
ALT	(IU/L) 70	(49-	108) 71	(45-	116) 74	(56-	92) 51	(41-	103)
AST	(IU/L) 100	(66-	147) 98	(64-	162) 104	(78-	128) 127	(34-	175)
FA	(IU/L) 162	(103-	247) 156	(103-	234) 204	(102-	275) 186	(96-	324)
γGT	(IU/L) 131	(50-	284) 123	(47-	265) 217	(82-	649) 77	(53-	208)
Total	bilirubin	(mg/dL) 2.6	(1.5-	6.1) 2.7	(1.4-	5.6) 2.6	(1.6-	7.2) 2.6	(2.2-	9.9)
Albumin	(g/dL) 3.3	(3-	3.6) 3.3	(2.9-	3.6) 3.4	(3.2-	3.8) 3.1	(2.6-	3.3)
INR 1.2	(1.1-	1.4) 1.2	(1.1-	1.4) 1.2	(1.1-	1.3) 1.6	(1.4-	1.7)
Creatinine	clearance	(mL/min) 66.8	(51.5-	88.4) 66.5	(52-	84.3) 74	(63.5-	96.8) 33	(30.1-	80.8)
Platelets	(1×103/μL) 82	(56-	126) 82	(61-	131) 75	(54-	112) 68	(46-	88)
MELD	scorea 15	(11-	19) 15	(11-	18) 12	(11-	17) 20	(20-	23)
CTP	Class	A/B/C,	% 14/59/27 14/61/25 22/64/14 0/20/80
CTP	scorea 8	(7-	10) 8	(7-	10) 7	(7-	8) 10	(9-	12)
Values	are	expressed	as	median	(IQR)	or	number	(%).
aData	are	calculated	after	excluding	two	patients	in	anticoagulant	oral	therapy.
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intrahepatic	portosystemic	shunt	(TIPS)	placement,	one	liver	failure	(cur-
rently	awaiting	re-	LT),	one	hepatic	encephalopathy,	two	HCC,	two	vari-
ceal	bleedings,	one	sepsis	and	one	portal	vein	thrombosis.	Two	patients	
had	extrahepatic	complications	(one	stroke	and	one	Parkinson’s	disease).
3.3 | Survival analyses
The	 overall	 survival	 of	 the	 study	 population	 is	 represented	 in	 the	
Figure	2A.	 Furthermore,	 we	 compared	 the	 survival	 curves	 of	 pa-
tients	divided	according	to	baseline	MELD	cut-	off	values	of	20	(me-
dian	value	 in	patients	who	died	during	 long-	term	follow-	up)	and	25	
(median	value	in	patients	who	died	during	treatment	or	shortly	after	
EOT)	 (Figure	2B,C).	The	survival	was	 lower	 in	both	MELD≥20	com-
pared	 to	MELD<20	 patients	 (Log-	rank	 test,	 χ2(1)=17.506,	P<.0001)	
and	 in	 MELD≥25	 compared	 to	 MELD<25	 patients	 (Log-	rank	 test,	
χ2(1)=12.551,	P<.0001).	Finally,	we	found	a	similar	overall	cumulative	
survival	of	FCH	patients	 compared	 to	 cirrhotic	ones	 (Log-	rank	 test,	
χ2(1)=1.313,	P=.252,	Figure	2D).
F IGURE  1 Enrolment	and	study	completion.	The	distribution	of	
the	patients	during	the	study	is	represented	in	a	flow	chart	showing	
the	number	of	subjects	at	each	time	point:	baseline,	weeks	4,	12	and	
24	of	treatment,	week	12	of	follow-	up	and	last	available	long-	term	
follow-	up.	The	reasons	of	dropouts	are	briefly	depicted
TABLE  2 Comparison	of	baseline	characteristics	and	outcomes	
between	cirrhotic	and	FCH	patients
Cirrhosis 
(n=52)
FCH 
(n=21)
P 
value
Male	gender 38	(73%) 16	(76%) 1
Age	(y) 55	(51-	64) 50	(48-	56) .011
BMI 23	(21-	26) 23	(21-	24) .235
Time	from	LT	(mo) 39	(20-	65) 11	(4.5-	12) <.001
Previous	antiviral	
treatment
33	(64%) 13	(62%) 1
Starting	RBV	dose	
(mg)
600	(400-	800) 800	(500-	800) .550
Starting	RBV	dose	
(mg/kg)
10.3	(6.8-	13) 11.6	(8-	13.2) .393
Genotype	1-	4 47	(90.4%) 19	(90.5%) 1
SOF+RBV/
SOF+RBV+PegIFN/
SOF+DCV	or	SMV,	n
38/9/5 16/5/0 .383
HCV-	RNA	(Log10	IU/
mL)
5.9	(5-	6.3) 6.3	(2.9-	9) .010
Total	bilirubin	(mg/dL) 2	(1.3-	3.3) 6.3	(2.8-	11.5) <.001
γ-	glutamyltransferase	
(IU/L)
91	(49-	174) 546	(77-	1100) .001
Albumin	(g/dL) 3.2	(2.9-	3.6) 3.3	(3-	3.8) .234
INR 1.3	(1.1-	1.4) 1.1	(1-	1.4) .021
Creatinine clearance 
(mL/min)
66	(49-	88) 69	(64-	97) .352
Platelets	(1×103/μL) 77	(53-	116) 93	(64-	128) .195
MELD	scorea 13	(11-	18) 17	(14-	20) .109
MELD≥25 5	(10%) 2	(10%) 1
MELD≥20 11	(22%) 6	(30%) .543
CTP	Class	A/B/C,	% 16/56/28 10/65/25 .739
CTP	scorea 9	(7-	10) 8	(7-	10) .726
SVR	(per-	protocol	
analysis)
31/47	(66%) 15/19	(79%) .383
Patients	with	SAE 16	(30.8%) 4	(19.2%) .393
Complications	at	last	
follow-	upb
8	(19.1) 1	(5.3) .251
Deaths	at	last	
follow-	up
10	(19.2%) 2	(9.6%) 0.488
Overall	survival	time	
after	treatment	
cessation	(d)
650	(480-	770) 769	(599-	808) .047
Values	are	expressed	as	median	(IQR)	or	number	(%);	categorical	variables	
were	compared	using	the	χ2	and	Fischer’s	exact	test	and	quantitative	vari-
ables	were	compared	by	the	Mann-	Whitney	test.	Bold	fonts	indicate	the	
statistically	significant	differences.
aData	are	calculated	in	71	patients	(after	excluding	two	patients	in	antico-
agulant	oral	therapy).
bData	are	calculated	in	patients	alive	at	last	follow-	up.
     |  5VUKOTIC eT al.
3.4 | Outcomes in patients with FCH and 
in cirrhotics
Baseline	characteristics	and	outcomes	of	FCH	and	non-	FCH	patients	
are	 presented	 in	 Table	 2.	One	 FCH	 died	 short	 after	 starting	 treat-
ment	and	one	underwent	 re-	LT	at	week	16.	Fifteen	of	19	obtained	
SVR12	 (79%,	 per-	protocol	 analysis).	 The	 virological	 relapsers	 were	
all	successfully	re-	treated	afterwards.	FCH	patients	showed	a	signifi-
cant	improvement	from	baseline	to	last	follow-	up:	bilirubin	(6.3	[2.8-	
11.5]	vs	1.1	[0.6-	2.5],	P<.0001),	γ-	GT	(546	[77-	1100]	vs	67	[35-	244],	
P<.0001),	albumin	(3.4	[3-	3.8]	vs	4.2	[3.7-	4.3],	P=.001)	and	MELD	(17	
[14-	20]	vs	10	[8-	13],	P<.0001).
Among	52	cirrhotics,	 the	SVR12	rate	was	66%.	Also	 in	this	sub-
group	 all	 relapsers	were	 successfully	 re-	treated	 and	experienced	 an	
improvement	of	baseline	vs	long-	term	observation	MELD	(13	[11-	18]	
vs	9	[7-	13],	P<.0001)	and	CTP	score	(9	[7-	10]	vs	5	[5,6],	P<.0001).
4  | DISCUSSION
Data	about	efficacy	of	DAA-	based	treatments	in	post-	LT	setting	have	
been	promising,14-22	but	to	our	knowledge	there	are	no	data	available	
on	long-	term	impact	 in	end-	stage	cirrhosis	and	FCH	cohorts.	 In	two	
studies	on	LT	recipients	 treated	with	SOF+SMV,17,18	SVR12	ranged	
F IGURE  2 Survival	curves.	Kaplan-	Meier	survival	curves	of	(A)	overall	study	population,	(B)	patients	stratified	according	to	baseline	MELD	
cut-	off	20,	(C)	patients	stratified	according	to	baseline	MELD	cut-	off	25,	(D)	patients	with	cirrhosis	compared	to	patients	with	FCH
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from	90%	to	93%	but	most	of	the	patients	had	not	an	advanced	dis-
ease,	 and	 FCH	was	 underrepresented.	 A	 phase-	2	 study	 on	 the	 LT	
cohort	treated	with	SOF+ledipasvir	showed	SVR12	rates	of	80%	for	
CTP-	B	and	~60%	for	CTP-	C	patients.20	A	phase-	3	open	 label	 study	
with	 SOF+DCV+RBV	 in	 55	 patients	 with	 post-	LT	 HCV	 recurrence	
showed	SVR	12	rate	of	94%.22	Notably,	this	cohort	had	no	patients	
with	FCH.	In	a	recent	study	utilizing	SOF+DCV	in	FCH,	22/23	(96%)	
patients	reached	SVR12	with	significant	clinical	improvement.19	None	
of	these	studies	reports	on	long-	term	outcomes.
Finally,	recently	published	data	on	126	LT	patients,	showing	long-	
term	functional	impact	and	fibrosis	regression	after	SOF-	based	treat-
ment	 had	 no	 FCH	 subjects	 included	 and	 described	 a	 fairly	 shorter	
follow-	up	respect	to	our	data.23
Our	results	show	that	DAAs-	based	treatments	are	able	to	induce	
a	 durable	 clinical	 improvement	 in	 severe	HCV	 recurrence,	 including	
FCH.	The	satisfactory	clinical	outcomes	allow	successful	re-	treatments	
in	patients	with	virological	failure.
The	 limitations	of	this	study,	starting	from	the	retrospective	col-
lection	of	the	information	on	follow-	up,	are	also	the	small	sample	size,	
a	noncentralized	evaluation	of	virological,	histological	and	laboratory	
data	and	 the	heterogeneity	of	 the	population	 in	 terms	of	 treatment	
schedule.
To	our	knowledge,	our	data	are	the	first	to	show	that	clinical	attain-
ment	of	DAAs-	based	post-	LT	therapy	is	maintained	over	a	long	period	
of	observation.	Patients	with	FCH	had	apparently	higher	SVR12	rate	
and	cumulative	 survival	 than	patients	with	 cirrhosis,	 although	 these	
differences	 did	 not	 reach	 statistical	 significance.	The	MELD,	mostly	
resulting	 from	high	bilirubin	values	 in	FCH	subjects,	was	 similar	be-
tween	these	two	subpopulations.	Still,	the	median	overall	survival	was	
significantly	 longer	 in	FCH	patients.	This	probably	 implicates	 that	 in	
FCH,	 characterized	 by	 extremely	 high	 baseline	 HCV-	RNA,	 the	 viral	
clearance	itself	brings	a	substantial	benefit	even	in	severe	cholestatic	
hepatitis	setting,	thus	prolonging	survival.	On	the	other	hand,	cirrhotic	
patients	with	very	advanced	disease	might	not	benefit	from	the	treat-
ment,	even	though	achieving	SVR12.
The	mortality	 is	 presumably	 due	 to	 the	 context	 of	 an	 advanced	
HCV	recurrence	wherefore	both	baseline	MELD	and	CTP	scores	were	
higher	in	deceased	patients	compared	to	the	ones	who	survived.
The	appropriate	patients’	selection	is	a	demanding	issue	because	
those	 with	 extremely	 advanced	 disease	 seem	 not	 to	 benefit	 even	
from	the	virological	response	and	are,	moreover,	more	fragile	towards	
possible	 adverse	 events.	 In	 our	 cohort,	 the	 baseline	MELD≥25	 and	
baseline	MELD≥20	emerged	as	valid	thresholds	for	the	prediction	of	
short-	term	and	long-	term	mortality,	respectively.	Patients	with	base-
line	MELD≥25	had	an	extremely	poor	survival	with	almost	all	events	
of	death	registered	early	during	treatment.	On	the	other	hand,	a	lower	
threshold	 as	MELD≥20	can	help	 identifying	 those	patients	who	are	
not	 as	 sick	 as	 not	 to	 survive	 the	 treatment	 but	who,	 despite	 HCV	
clearance,	do	not	survive	long	afterwards.	Nevertheless,	it	should	be	
prospectively	explored	whether	and	which	cut-	off	MELD	value	could	
effectively	detect	a	“too-	sick-	to-	be-	treated”	population.
Our	results	show	the	long-	term	functional	effectiveness	of	DAAs-	
based	 treatments	 for	 severe	 HCV	 recurrence	 comprising	 FCH.	 The	
treatment	might	be	futile	in	certain	patients;	therefore,	future	studies	
are	 necessary	 to	 identify	 a	valid	 selection	 strategy	 in	 extremely	 ad-
vanced	settings.
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